Insmed (INSM) PT Lowered to $203 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street futures fall as oil, Treasury yields rise on Iran tensions
- Oil prices fall after hitting over one-month high; traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Insmed (INSM) PT Lowered to $195 at RBC Capital
December 18, 2025 4:19 AM ESTRBC Capital analyst Leonid Timashev lowered the price target on Insmed (NASDAQ: INSM) to $195.00 (from $215.00) while maintaining a Outperform rating.
The analyst comments "This afternoon, INSM reported that their ph.II BiRCH study of brensocatib in CRSsNP failed, and the program... More
Insmed (INSM) PT Lowered to $195 at Leerink Partners
December 18, 2025 4:11 AM ESTLeerink Partners analyst Joseph P. Schwartz lowered the price target on Insmed (NASDAQ: INSM) to $195.00 (from $227.00) while maintaining a Outperform rating.
The analyst comments "After the market close, INSM reported that the Phase 2 BiRCh trial for brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP) missed on the primary and all secondary endpoints. While we had hoped that the... More
Insmed (INSM) PT Lowered to $167 at Wolfe Research
December 18, 2025 3:53 AM ESTWolfe Research analyst Andy Chen lowered the price target on Insmed (NASDAQ: INSM) to $167.00 (from $229.00) while maintaining a Outperform rating.
The analyst comments "Postmarket, stock is down 19% (consistent with a priori buyside expectation of -20 to -25%). We continue to believe that buyside is assigning slightly less than $6B peak sales to Brinsupri in bronchiectasis, suggesting that the current stock level... More
Insmed discontinues nasal polyps drug program after trial fails
December 17, 2025 4:01 PM ESTInsmed Incorporated (NASDAQ: INSM) announced that its Phase 2b BiRCh study of brensocatib for chronic rhinosinusitis without nasal polyps failed to meet primary or secondary efficacy endpoints, leading the company to discontinue the program.
The study tested two doses of brensocatib against placebo in 288 patients over 24 weeks. Results showed placebo patients had a least squares mean... More
Insmed (INSM) halted, news pending
December 17, 2025 4:01 PM ESTInsmed (NASDAQ: INSM) halted, news pending
... MoreInsmed (INSM) PT Raised to $230 at Cantor Fitzgerald Brenso Potential
December 16, 2025 6:48 AM ESTCantor Fitzgerald analyst Olivia Brayer raised the price target on Insmed (NASDAQ: INSM) to $230.00 (from $216.00) while maintaining a Overweight rating.
The analyst commented, "We think brenso has a good chance to show a benefit in CRSsNP (on top of a steroid... More
Insmed (INSM) PT Raised to $234 at Wells Fargo
December 16, 2025 6:20 AM ESTWells Fargo analyst Ben Burnett raised the price target on Insmed (NASDAQ: INSM) to $234.00 (from $217.00) while maintaining a Overweight rating.... More
